CALA vs. EVLO, GNCAQ, GNCA, ARDS, STAB, AMPE, CMRA, EFTR, CLVR, and ONCSQ
Should you be buying Calithera Biosciences stock or one of its competitors? The main competitors of Calithera Biosciences include Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), Comera Life Sciences (CMRA), eFFECTOR Therapeutics (EFTR), Clever Leaves (CLVR), and OncoSec Medical (ONCSQ). These companies are all part of the "pharmaceutical products" industry.
Calithera Biosciences vs.
Evelo Biosciences (NASDAQ:EVLO) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
Calithera Biosciences received 171 more outperform votes than Evelo Biosciences when rated by MarketBeat users. However, 60.50% of users gave Evelo Biosciences an outperform vote while only 55.09% of users gave Calithera Biosciences an outperform vote.
In the previous week, Calithera Biosciences had 1 more articles in the media than Evelo Biosciences. MarketBeat recorded 1 mentions for Calithera Biosciences and 0 mentions for Evelo Biosciences. Evelo Biosciences' average media sentiment score of 0.32 beat Calithera Biosciences' score of 0.00 indicating that Evelo Biosciences is being referred to more favorably in the media.
0.3% of Evelo Biosciences shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Evelo Biosciences has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of -2.38, indicating that its stock price is 338% less volatile than the S&P 500.
Summary
Evelo Biosciences and Calithera Biosciences tied by winning 4 of the 8 factors compared between the two stocks.
Get Calithera Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Calithera Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:CALA) was last updated on 5/22/2025 by MarketBeat.com Staff
